


conferenceseries.com

946th Conference

Scientific Program

Proceedings of

7th European Biosimilars Congress

May 15-16, 2017 Munich, Germany

Conference Series - America

One Commerce Center-1201, Orange St. #600, Wilmington,
Zip 19899, Delaware, USA
P: +1-702-508-5200, F: +1-650-618-1417

Conference Series - UK

Kemp House, 152 City Road, London EC1V 2NX, UK
Toll Free: +1-800-014-8923

Day 1 May 15, 2017

09:30-10:00 Registrations

Lilli Palmer

conferenceseries.com 10:00-10:10 **Opening Ceremony**

Keynote Forum

10:10-10:15	Introduction
10:15-11:05	Title: The commercial landscape for biosimilars: Planning in an uncertain environment **Arthur G. Cook**, ZS Associates, USA
	Networking & Refreshment Break 11:05-11:30 @ Breakout Area
11:30-12:20	Title: Intellectual property and regulatory interplay in biosimilars **Christoph Volpers**, Michalski Hüttermann & Partner, Germany
	Group Photo 12:20-12:35 @ Breakout Area
	Lunch Break 12:35-13:35 @ Restaurant

Sessions: Innovative Approach for Biosimilars | Clinical Development of Biosimilars | Emerging Biosimilars in Therapeutics

Session Chair: Tim Demuth

	Session Introduction
13:35-14:15	Title: CMC considerations for biosimilar drug development **Ulrike Konrad**, Karl Ruprecht Universität, Germany
14:15-14:55	Title: Search for unknown immunogenicity: An overview **Rosa Helena Bustos**, University of La Sabana, Colombia
	Networking & Refreshment Break 14:55-15:25 @ Breakout Area
15:25-16:05	Title: Development of Etanercept biosimilar Erelzi™ **Tim Demuth**, Sandoz, Germany
16:05-16:45	Title: Development and *in-vivo* evaluation of Ofloxacin gastro-retentive drug delivery system **Dina E Abo Elezz**, Pharos University, Egypt
	Panel Discussion

Day 2 May 16, 2017

Lilli Palmer

Keynote Forum

10:10-10:15	Introduction
10:15-11:05	Title: How AbbVie tries to fend off world's blockbuster No 1 from generic competition **Ulrich Storz**, Michalski Hüttermann & Partner, Germany
	Networking & Refreshment Break 11:05-11:25 @ Breakout Area
11:25-12:25	Title: Innovative, cost effective solution for self-administration of Bio-similar drugs **Tsachi Shaked**, E3D Elcam Drug Delivery Devices, Israel **Menachem Zucker**, E3D Elcam Drug Delivery Devices, Israel
	Lunch Break 12:25-13:25 @ Restaurant

Sessions: Biosimilar Market and Cost Analysis | Analytical Strategies for Biosimilars | Globalization of Biosimilars

Session Chair: Tim Demuth

	Session Introduction
13:25-14:05	**Title: Evidence-based approach of CT-P13 to meet the expectations of different stakeholders** **Stanley Seung Suh Hong,** Celltrion Healthcare Co. Ltd., South Korea
14:05-14:45	**Title: Multilevel characterization of biosimilars by CE-LIF and CE-MS** **Andras Guttman,** University of Pannonia, USA
14:45-15:25	**Title: Development of a methodology for the evaluation of tumor necrosis factor antibody (anti-TNF-alpha) in patients with treatment of biological products through the use of Nanobiosensors** **Efraín Esteban,** University of La Sabana, Colombia
15:25-16:05	**Title: Study of liver toxicity and its reversibility of Cassytha filiformis defatted ethanolic extract on mice** **Armenia Nazar,** University of Andalas, Indonesia
	Networking & Refreshment Break 16:05-16:30 @ Breakout Area
	Poster Presentations 16:30-17:30 @ Meeting Halls
EBP 01	**Title : Polymer-based prefillable syringes designed to minimize the aggregation risk of sensitive biodrugs** **Katsuyuki Takeuchi, Terumo Corporation, Japan**
EBP 02	**Title: Improved biologics workflow utilizing a single, automated platform to effectively monitor protein stability** **Marco Schwieder, NanoTemper Technologies GmbH, Germany**
EBP 03	**Title : Investigation of chemoprevention properties of Halopteris scoparia brown algae by using in vivo bioluminescent imaging"** **Özgenur Erdokur, Ege University, Turkey**
EBP 04	**Title : Inflectra-our experience on immunogenicity (case series)** **Rodica Olteanu, Colentina Clinical Hospital, Romania**
EBP 04	**"Title : Development of a methodology for the evaluation of tumor necrosis factor antibody (anti-TNFalpha) in patients with treatment of biological products through the use of nanobiosensors** **Zapata C, University of La Sabana, Colombia**
EBP 04	**Title : How can modeling and simulation optimize the clinical development of adalimumab biosimilar candidates?** **Bernardo Miguel-Lillo, SGS Exprimo, Belgium**
	Award Ceremony

